The Split-Second Decision Impacting 600M+ People
“I could either hit him, or lay the thing down,” once-renowned surgeon Dr. Gaetano Scuderi said of a fateful accident on his old Ducati motorcycle.
The seven-year surgery hiatus that followed may help 500M+ people, because it led to the creation of Cytonics.
Cytonics developed what could be the first and only treatment that’s shown the ability to reverse the effects of osteoarthritis, the world’s most common cause of joint pain. This therapy attacks the root cause of the disease, potentially offering a solution Big Pharma has chased for years.
But that's only scratching the surface of why 7,000+ investors have already backed Dr. Scuderi's vision.
- Breakthrough: If approved, CYT-108 could be the first therapy in history to actually halt cartilage destruction and promote regrowth.
- Traction: $32M raised from 7,000+ investors, including a seven-figure from pro athletes Rener and Eve Gracie, backed by partnerships with Stanford and Scripps Research.
- Opportunity: Everyday investors have the limited-time chance to participate in an early-stage biotech investment opportunity that’s historically been reserved for VCs and institutional investors.
Providing true relief is a massive opportunity in the $500B osteoarthritis treatment market. Even better, you can join them as an investor at the pre-certification stage and unlock exclusive rewards like up to 15% bonus stock.
But you only have until March 26 to take advantage. Invest in Cytonics and help them bring this breakthrough treatment to market.
This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/